Is CyberArk Stock a Buy, Sell or Hold?
CyberArk Software (NASDAQ:CYBR), the identity security and management firm, has…
Sell
48
FORM Quote, Financials, Valuation and Earnings
Last price:
$31.12
Seasonality move
:
9.57%
Day range:
$30.75 - $32.00
52-week range:
$30.22 - $63.63
Dividend yield:
0%
P/E ratio:
34.96x
P/S ratio:
3.20x
P/B ratio:
2.55x
Volume:
1.6M
Avg. volume:
824K
1-year change:
-29.07%
Market cap:
$2.4B
Revenue:
$763.6M
EPS (TTM):
$0.89
Analysts' Opinion
-
Consensus RatingFormFactor has received a consensus rating of Hold. The company's average rating is a Hold based on 3 Buy ratings, 6 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $42.22, FormFactor has an estimated upside of 35.72% from its current price of $31.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $34.00 representing 100% downside risk from its current price of $31.11.
Fair Value
-
According to the consensus of 9 analysts, FormFactor has 35.72% upside to fair value with a price target of $42.22 per share.
FORM vs. S&P 500
-
Over the past 5 trading days, FormFactor has underperformed the S&P 500 by -3.27% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
FormFactor does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
FormFactor has grown year-over-year revenues for 5 quarters straight. In the most recent quarter FormFactor reported revenues of $189.5M.
Earnings Growth
-
FormFactor earnings have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter FormFactor reported earnings per share of $0.12.
Enterprise value:
2.1B
EV / Invested capital:
--
Price / LTM sales:
3.20x
EV / EBIT:
25.88x
EV / Revenue:
2.71x
PEG ratio (5yr expected):
0.09x
EV / Free cash flow:
26.12x
Price / Operating cash flow:
30.87x
Enterprise value / EBITDA:
18.33x
Gross Profit (TTM):
$307.9M
Return On Assets:
6.13%
Net Income Margin (TTM):
9.12%
Return On Equity:
7.43%
Return On Invested Capital:
7.32%
Operating Margin:
4.14%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $747.9M | $663.1M | $763.6M | $168.2M | $189.5M | |
| Gross Profit | $296M | $258.6M | $307.9M | $67.9M | $73.6M | |
| Operating Income | $54.8M | $9.8M | $44.2M | $8.3M | $7.9M | |
| EBITDA | $96.4M | $127.1M | $112.7M | $96.7M | $52.3M | |
| Diluted EPS | $0.64 | $1.06 | $0.89 | $0.97 | $0.12 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $487.1M | $524M | $474.6M | $573.8M | $605.1M | |
| Total Assets | $963.2M | $1B | $1B | $1.1B | $1.1B | |
| Current Liabilities | $154.6M | $148.8M | $149.7M | $131.1M | $131.3M | |
| Total Liabilities | $219.1M | $204.7M | $199.9M | $198M | $198.4M | |
| Total Equity | $744.1M | $815.8M | $808.3M | $908.8M | $947.8M | |
| Total Debt | $34.5M | $24.4M | $15.4M | $14.4M | $13.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $131.8M | $64.6M | $117.5M | $9.3M | $35.9M | |
| Cash From Investing | -$75.7M | $29M | -$33.5M | $79M | -$7.3M | |
| Cash From Financing | -$95.9M | -$22.7M | -$64.6M | -$21.4M | -$18.4M | |
| Free Cash Flow | $66.5M | $8.6M | $79.1M | -$683K | $28.3M | |
FORM
Sector
Market Cap
$2.4B
$88.2M
Price % of 52-Week High
48.9%
60.41%
Dividend Yield
0%
0%
Shareholder Yield
-0.28%
0.83%
1-Year Price Total Return
-29.07%
-16.67%
Beta (5-Year)
1.075
0.910
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Sell
Level
$31.85
200-day SMA
Sell
Level
$45.26
Bollinger Bands (100)
Sell
Level
35.33 - 44.27
Chaikin Money Flow
Buy
Level
41.7M
20-day SMA
Sell
Level
$32.65
Relative Strength Index (RSI14)
Sell
Level
36.55
ADX Line
Sell
Level
32.26
Williams %R
Neutral
Level
-72.6154
50-day SMA
Sell
Level
$37.37
MACD (12, 26)
Sell
Level
-1.52
25-day Aroon Oscillator
Sell
Level
-52
On Balance Volume
Sell
Level
-31.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (11.7986)
Buy
CA Score
(Annual)
Level (1.6081)
Buy
Beneish M-Score
(Annual)
Level (-2.6305)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (-3.0222)
Buy
Piotroski F Score
(Annual)
Level (8)
Sell
Quality Ratio Score
Level (4)
Buy
Fundamental Score
Level (9)
Revenue Forecast
Earnings per Share Forecast
Company Profile
FormFactor Inc is a provider of electrical and optical test and measurement technologies along the full semiconductor product lifecycle - from characterization, modeling, reliability, and design de-bug, to qualification and production test.. The company operates in two reportable segments namely Probe Cards Segment and the Systems Segment. Sales of probe cards and analytical probes are included in the Probe Cards Segment, while sales of probe stations and thermal sub-systems are included in the Systems Segment. Probe cards generate the maximum revenue from its operations. It offers multiple product lines which include analytical probes, probe stations, thermal sub-systems, and related services.
Stock Forecast FAQ
In the current month, FORM has received 3 Buy ratings 6 Hold ratings, and 0 Sell ratings. The FORM average analyst price target in the past 3 months is $42.22.
-
Where Will FormFactor Stock Be In 1 Year?
According to analysts, the consensus estimate is that FormFactor share price will rise to $42.22 per share over the next 12 months.
-
What Do Analysts Say About FormFactor?
Analysts are divided on their view about FormFactor share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that FormFactor is a Sell and believe this share price will drop from its current level to $34.00.
-
What Is FormFactor's Price Target?
The price target for FormFactor over the next 1-year time period is forecast to be $42.22 according to 9 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 6 analysts rate the stock a Hold.
-
Is FORM A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for FormFactor is a Hold. 6 of 9 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of FORM?
You can purchase shares of FormFactor via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase FormFactor shares.
-
What Is The FormFactor Share Price Today?
FormFactor was last trading at $31.12 per share. This represents the most recent stock quote for FormFactor. Yesterday, FormFactor closed at $31.11 per share.
-
How To Buy FormFactor Stock Online?
In order to purchase FormFactor stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Amazon Stock Still Worth Staking On?
Amazon.com Inc (NASDAQ: AMZN) posted one of its strongest years…
Is Palantir a Good Stock to Buy?
Palantir Technologies (PLTR) stock soared to its highest level in…
Stock Ideas
Buy
55
Is AAPL Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 36x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 40x
Alerts
Sell
50
RGC alert for Mar 22
Regencell Bioscience Holdings [RGC] is up 27.82% over the past day.
Sell
36
VMI alert for Mar 22
Valmont Industries [VMI] is down 12.54% over the past day.
Buy
61
ALNY alert for Mar 22
Alnylam Pharmaceuticals [ALNY] is up 11.7% over the past day.
